Blood-brain barrier evaluation and measurement of plasma and CSF TNF-α in patients divided by neurological diagnosis
| Neurological diagnosis | Asymptomatic | PML | HIVE | OIs non-PML |
|---|---|---|---|---|
| QAlb: | ||||
| Patients tested | 9 | 15 | 8 | 24 |
| Median value (range) | 4.0 (2.9–6.7) | 5.1 (3.0–16.6) | 6.9 (5.8–14) | 13.7 (4.0–43.7) |
| Patients with Qalb>8 | 0 | 2 (13.3%) | 3 (37.5%) | 22 (91.6%) |
| CSF TNF-α: | ||||
| Patients with detectable TNF-α | 8/12 | 13/17 | 9/9 | 25/26 |
| Median value (range) | 4.2 (3.2–6.7) | 6.0 (3.2–10.5) | 11.3 (7.0–16.0) | 17.8 (3.5–532) |
| Patients with TNF-α >10 | 0 | 1 (7.6%) | 5 (55.5%) | 19 (76%) |
| Plasma TNF-α: | ||||
| Patients tested | 11 | 11 | 8 | 22 |
| Median value (range) | 36 (12.8–88) | 22 (13.7–146) | 50.1 (10.4–127.4) | 38.3 (23.0–127) |
| Patients with TNF-α >10 | 11 (100%) | 11 (100%) | 8 (100%) | 22 (100%) |
PML=progressive multifocal leukoencephalopathy; HIVE=HIV-1 leukoencephalopathy; OIs=opportunistic infections). QAlb⩾8 signified an impaired blood-brain barrier. TNF-α values are expressed as pg/ml. Values of TNF-α up to 10 pg/ml were regarded as normal. Statistical analysis. QAlb value: asymptomatic v PML, p=0.12; HIVEv PML, p=0.07; OIs non-PMLv PMl, p<0.001.
Patients with QAlb ⩾8: asymptomaticv PML, p=0.38; HIVEv PML, p=0.20; OIs non-PMLv PMl, p<0.001
CSF TNF-α concentrations: asymptomatic vPML, p=0.32; HIVE v PML, p<0.001; OIs non-PML v PMl, p<0.001.
Patients with TNF-α>10 pg/ml: asymptomaticv PML, p=0.61; HIVEv PML, p=0.02; OIs non-PMLv PMl, p<0.001.